1. 1
F F F F F F
F F
. . 2553 2555
1)
F F F F
F F F F F F F
F F F F
F F F F F F F
F F F F
F F F F F F (Diagnosis
Related Group: DRG) F F F
F F F F F F F
F (Fee-for-service)
F F F F F F
F F F F
F F F F F
F F F F F
. . 2549 - 2551 F 37,004 F 46,481.05
54,904.48 F F 25.61 18.12 F F F
F F F F
F F F F F F F F
F F F F 46 . .
2545 F 70 . . 2551 F F F
F F F FF F F F
( F 83) F F F F F
F F F F F F
F F F F F F F F
F F F F F F
F F F
F
F F F F
F F F F FF

2. 2
F F F F F
F F F F F F F F
F F FF F
2) F
2.1 F
F F F F
F F F F FF F
2.2 F
2.2.1 F F F
F F F F F F
(process indicators) F (outcomes indicators)
F F F F
2.2.2 F FF
F F
F
2.2.3 F F F FF F F
F F F (reference price), F F
(negative lists) F F F F (drug costs sharing)
F FF
2.2.4 F F F F (prospective
payments) F F
F FF F F
3)
FF F F
F F FF F F
F F F FF F F
F F F
F F F F
F F F
F F F F F
F F F F

3. 3
F F F F FF F
(Drug Utilization Review) F
F F FF F
F F FF F F academic
detailing, reference price, negative list, co-payment etc.
F F F F F F
(prospective payments) F F F F F
F F F
F
1 2 3
2.2.1
F F F
2.2.2
F FF F . (DUR)
2.2.3
F FF F academic
detailing, reference price,
negative list, co-payment etc.
2.2.4 F F F
. F
4)
4.1 F F
F F F

4. 4
F F F FF 34 F F F
F F 3
4.2 F F F F
• F F F
• F F FF F F F F F F ( F
F F F F )
4.3
F F F F F F F F
F F F F
F F F F F F
I. F
F
1. ARB: ACEI:
Candesartan, Irbesartan, Losartan, Captopril, Cilazapril, Enalapril,
Olmesartan, Telmisartan, Valsartan, Fosinopril, Imidapril, Lisinopril,
and their combination with Perindopril, Quinapril, Ramipril
hydrochlorothiazide
2. - Single-source statins: Multi-source statins:
Atorvastatin, Fluvastatin, Pravastatin, Simvastatin
Rosuvastatin
- New antilipidemics:
Acipimox, Ezetimibe
3. F Clopidogrel, Ticlopidine Single low-dose (grain I) aspirin
4. Single-source PPI: - Multi-source PPI:
Esomeprazole, Lansoprazole, Omeprazole
Pantoprazole, Rabeprazole - H2A:
Cimetidine, Famotidine, Ranitidine
5. F Coxibs: Conventional NSAID:
Celecoxib, Etoricoxib, Lumiracoxib, Diclofenac, Ibuprofen, Indomethacin,
Rofecoxib Ketoprofen, Leflunomide, Lozoprofen,
Mefenamic, Meloxicam, Nabumetone,
Naproxen, Nimesulide, Piroxicam,
Sulindac, Tenoxicam, Tiaprofenic
II. F / F
F F F

5. 5
1. Bisphosphanates:
Alendronate, Etidronate,
Pamidronate, Residronate
SERMs:
Raloxifene, Tibolone
Others:
Teriparatide
2. Glimepiride, Rosiglitazone, Acarbose, Glibenclamide,
Voglibose Gliclazide, Glipizide, Metformin,
Pioglitazone, Repaglinide
3. Glucosamine
Garbapentin
4.4 F F F F F F
(process indicators) F (outcome indicators) F FF
F F F F F
F F F F
F F F F
F F F threshold F 30, 60 F F F
F (Medicine Procession Ratio)
F polypharmacy F
F FF F F F F F F
F FF F FF F F F F F F
4.5. F F F (DUR) F F F F
F FF F F F F
F F F F F
F F
F F F / F F F F F
F
4.6 F F F F F F
F F F F
F FF F F F F

6. 6
F F
(Drug Utilization Review) F F
F F F FF F F
F F FF
F F F F
F FF F F F
F F F
F
4.7 F F F
F FF F F F F
F F F F
F 4.4 4.5 F
• F F F F F F F
F (academic detailing) F F
• F F (Reference price)
F F (Negative list)
• F F F F (Drug cost sharing)
4.8 F F F (Prospective payment) F
F F FF F F FF F
F F F F F F F
F F F F F
F F F F F F F
F F F F F F
F F F F F F
F F F
5)
F F
F F F 2553-2555 F
F F F F F
F F F

7. 7
5.1 F F F F F F
F F
F F F
- F F F F F F F F F
F
- F F FF F
- F
- F F F F F F 12
5.2 F F F F F F
F F ( ) F FF
F ( F F FF ) F (hospital)
F F F F (prescriber)
- F F F
- F . F
- F F F F
- F F
- F F F
5.3 F F F F
(DUR)
- F F
F F F FF
F
- F F F F FF F F
F
- F F F F F F
F F F
- F F F F F
F F F F F

8. 8
- F F F F F FF
- F
- F F F
F
5.4 F F F
F F F F (Knowledge management of DUR) F
F F F FF F
F F F F F F
F
- F
F FF
- F F F F F
- F F F F F F
- F F F F F
5.5 F F F F
F F F F Academic detailing, Reference
price, Negative list, Drug cost sharing
- F F F F
- F F F F F - F
F
- F F F
- F F
F F
- F F
F F F F F F F
5.6 F F FF
F F F F ( F F (point system) F
(per visit i.e. ACG) F (Differential capitation)
F ) F F
- F

9. 9
- F F
- F F
- F F F F F
- / F F F
-
F
- F F F F F F F F
6)
F
1) . .
2) . F F
3) . . F F F
4) . F 17
5)
F F F F
F F
F F F
3 F F F
1) F F /F F
2) F FF F
3)
F F
. F F F F
7) F
F
F F F F
F F F
F F F
F F F F F F F F- F

10. 10
F F F F F F F F
F F F F F F
F F F F
7.1 F F
F
7.2 F F F F
7.3 F F F F F
F
7.4 F F F F F F F F F
F F F F
7.5 F F F F . . . IHPP
8) F F
8.1 F F F
F F F F F F
F F
F FF F F F F
F F F
8.2 F F F F
F F F F F
F F F F
F F F
8.3 F F F F
F F
F F F F F FF F
F F F F
9) F F
.- 2553 2554 2555
. 1 2 3 4 5 6 7 8 9 10 11 12
F • • • • • • • • • • • •

11. 11
• • •
F FF
• • • •
F FF
F •
F F
9.1 F F F F
F F
F F F
FF F F F F
9.2 F F F F F F
F F F F
F F F F F
F F F F F
9.3 F F F F F F
F F F F F F
F F F F FF
F F F

12. 12